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Antibiotic Resistance
Antibiotics are used to prevent and treat bacterial infections
Antibiotic resistance occurs when bacteria change in
response to the use of antibiotic treatment
Bacteria, not humans or animals, become antibiotic-resistant
These resistant bacteria may infect humans and animals, and the
infections they cause are harder to treat
Antibiotic resistance leads to higher medical costs, prolonged
hospital stays, and increased mortality

Antibiotic Resistance
Antibiotic Resistance ECDC video
https://vimeo.com/181041782
Antibiotic Resistance
We urgently need to change the way antibiotics are used and
prescribed
Even if new antibiotics are developed, without behavior change,
antibiotic resistance will remain a major threat
Haemophilus influenzae
H. influenzae, a human-restricted pathogen, can cause life-threatening
infections such as pneumonia, bacteremia, and meningitis
Is also a key etiological agent of upper and lower respiratory tract
infections in both adults and children
It is classified as encapsulated (serotypes a-f) or no capsulated (NCHi),
depending on the presence or absence of a polysaccharide capsule
Haemophilus influenzae
Hib has long been a major cause of morbidity and mortality, especially in
Bajanca P, Canica M (2004) Emergence of nonencapsulated and encapsulated non-b-type invasive Haemophilus influenzae isolates in Portugal (1989-2001). J Clin Microbiol 42
children ≤5 years old
In Portugal, Hib vaccination was implemented in NIP in June 2000, for all
children of pre-school age (≤5 years old)
nearly extinction of Hib disease
increase in non-Hib disease, especially of NCHi in all age groups
Most cases of H. influenzae invasive disease occurring in Portugal are
now due to fully susceptible NCHi strains
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isolates in Portugal (1989-2001). J Clin Microbiol 42 (2):807-810
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Ampicillin Resistance Mechanisms in 
Haemophilus influenzae
Beta-lactams have been extensively used in the therapy for H. influenzae
infection, but, ampicillin-resistant strains have emerged and spread in 
early 70s 
Two major mechanisms are involved in ampicillin resistance
the enzymatic mechanism: β-lactam hydrolysis due to the production of 
β-lactamase, either TEM-1 type or ROB-1 type (rarely)
the non-enzymatic mechanism: decreasing affinity of β-lactams for 
altered penicillin-binding proteins (PBPs) 
Medeiros, A. A., and T. F. O'Brien. 1975. Lancet i:716-719
Rubin LG, Medeiros AA, Yolken RH, Moxon ER (1981) Lancet 2 (8254):1008-1010
Mendelman, P. M., D. O. Chaffin, and G. Kalaitzoglou. 1990. J. Antimicrob. Chemother. 25:525-534
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Strains exhibiting the non-enzymatic mechanism of resistance are called
β-lactamase-nonproducing ampicillin resistant strains (BLNAR) and have
been increasingly described worldwide
Strains possessing both mechanisms, β-lactamase and altered PBPs, are
defined as
β-lactamase-positive amoxicillin/clavulanic acid-resistant (BLPACR) and
seem to be increasing, after their first description in the USA
BLNAR strains show reduced susceptibility not only to ampicillin but also
to other β-lactam antibiotics, particularly cephalosporins
It is recommended that we should considered these strains resistant to all
β-lactam antibiotics, despite apparent in vitro susceptibility
Doern GV, Brueggemann AB, Pierce G et al. Antimicrob Agents Chemother 1997; 41: 292-97
Tristram S, Jacobs MR, Appelbaum PC (2007) ;Clin Microbiol Rev 20 (2):368-389
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In the microbiological point of view it is difficult to define BLNAR strains
the strain must be β-lactamase negative and have an ampicillin MIC equal 
or above the CLSI resistant breakpoint (≥4.0 mg/L)
strains with an MIC of 2.0 mg/L present difficulties, as they fall in the 
intermediate category
In addition, there is no international consensus on ampicillin breakpoints; 
for example, EUCAST has a different resistance breakpoint (>1.0 mg/L) 
and other systems have their own resistance breakpoints
Since we are in a World Congress I will consider CLSI breakpoints
The lack of a consensus and the broad range of ampicillin MICs associated 
with BLNAR strains is demonstrated by the range of ampicillin breakpoints 
used in various surveillance studies: from ≥1.0 mg/L to ≥4.0 mg/L. A few 
researchers start at ≥0.5 mg/L
CLSI and EUCAST breakpoints
Breakpoints used to determine susceptible, intermediate, and resistant 
categories for H. influenzae based on CLSI and EUCAST interpretative 
breakpoints
Breakpoint mg/L 
Antimicrobial CLSI EUCAST
Ampicillin S≤1 I=2 R≥4 S≤1 R>1
Amoxicillin/
Clavulanate
S≤4 R≥8 S≤2 R≥4
Overlap of MIC ranges according to different resistance mechanisms
Tristram S, Jacobs MR, Appelbaum PC (2007);Clin Microbiol Rev 20 (2):368-389. Adapted from Hasegawa et al., 2006 and Sanbongi et al., 2006
Hasegawa K, Chiba N, Kobayashi R et al. Antimicrob Agents Chemother 2004; 48: 1509-14.
Sanbongi Y, Suzuki T, Osaki Y et al. Antimicrob Agents Chemother 2006; 50: 2487-92
Antibiotic
Genotype (n) MIC (mg/L)
Susceptibility class 
(%)
MIC50 MIC90 MIC-range S I R
Ampicillin gBLNAS (66) 0.25 1 0.12-2 100 0 0
Susceptibilities to β-lactam antibiotics of 240 H. influenzae (2001-2008) 
isolates grouped in genotypes based on the presence/absence of ftsI
mutations
gBLPAR (33) 64 256 4-512 0 0 100
gBLPACR (47) 128 512 8->512 0 0 100
gBLNAR (94) 2 2 1-8 42.6 52.1 5.3
Amoxicillin/
clavulanate gBLNAS (66) 0.5 1 ≤0.25-4 100 0 0
gBLPAR (33) 2 2 0.5-4 100 0 0
gBLPACR (47) 2 4 1-4 100 0 0
gBLNAR (94) 2 4 ≤0.25-4 100 0 0
Determination of Antimicrobial Susceptibility (MiCroSTREP plus
Panels)- Minimum Inhibitory Concentration - MIC - mg/L
Methods
Ampicillin
Amoxicillin/Clavulanate
Cefepime
Ciprofloxacin
Chloramphenicol
Tetracycline
Cefotaxime
Cefuroxime
Cefaclor
Meropenem
Trimethoprim-
Sulfamethoxazole
Rifampin
Azithromycin
Siemens Healthcare Diagnostics Inc. / Beckman Coulter
Methods
β-lactamase characterization by nitrocefin or PCR
(TEM-1 or ROB-1)
Serotyping: Presence/absence of capsule by PCR
according to Falla et al., 1994
Amplification and Sequencing of ftsI gene (1832 bp)
according to Cerquetti et al., 2007
Falla TJ, Crook DW, Brophy LN, Maskell D, Kroll JS, Moxon ER (1994);J Clin Microbiol 32 (10):2382-2386
Cerquetti M, Giufre M, Cardines R, Mastrantonio P (2007); Antimicrob Agents Chemother 51 (9):3155-3161
Analysis of substitutions in ftsI gene
Bioinformatic tools
Reverse Complement
Analysis
(http://www.bioinformatics.org/sms/rev_comp.html)
Expasy Translate Tool (Translate nucleotide sequence)
(http://web.expasy.org/translate/)
BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi)
β-lactamase production
Portuguese H. influenzae collection- more than 13500 
strains, collected since 1989
β-lactamase production have been determined with
Nitrocefin and/or PCR multiplexTEM/ROB
Percentage of β-lactamase producers are ~10%, with 
variations from year to year
Most of  characterized strains by PCR are TEM-1 
Two strains are ROB-1 producers
One strain is TEM-2 producer
Groups and subgroups
BLNAR strains can be categorized by sequencing the ftsI gene that
encodes the transpeptidase region of PBP3; ftsI H. influenzae gene have 3
highly conserved amino acid motifs which are essential for function:
STVK- S327TVK, SSN- S379SN, and KTG- K512TG
The BLNAR strains are categorized into 3 groups (I, II, and III) based on
the presence/absence of different amino acid substitutions in the
neighborhood of these conserved PBP3 motifs (Ubukata et al., 2001)
Most isolates had Asp350Asn substitution
In addition:
Group I strains had Arg517His near the conserved Lys-Thr-Gly (KTG)
motif
Group II strains had Asn526Lys near the conserved Lys-Thr-Gly (KTG)
motif
Group III strains had Met377Ile, Ser385Thr, and Leu389Phe near the
conserved Ser-Ser-Asn (SSN) motif, in addition toAsn526Lys
Ubukata K, Shibasaki Y, Yamamoto K et al.; Antimicrob Agents Chemother 2001; 45: 1693-99
Groups and soubgroups
Group II strains were further divided into subgroups a, b, c,
and d, according to the presence of other substitutions (Dabernat
et al, 2002)
Subgroup IIa: the only observed substitution was 
Asn526Lys. 
Subgroup IIb: Ala502Val, along with other substitutions: 
Asp350Asn and Gly490Glu, Asp350Asn and Ala437Ser 
subgroup IIc, Ala502Thr 
subgroup IId, Ile449Val
Later, in 2007, group III-like was described (Garcia-Cobos et al., 
2007) 
Met377Ile e Ser385Thr in SSN motif 
Arg517His and Thr532Ser in the KTG motif
Asp350Asn and Ser357Asn in (Ser-Thr-Val-Lys) STVK motif
Dabernat H, Delmas C, Seguy M et al.; Antimicrob Agents Chemother 2002; 46: 2208-18
García-Cobos S, Campos J, Lázaro E et al.;Antimicrob Agents Chemother 2007; 51: 2564-73
Antibiotic resistance vs Groups
Strains with decreased ampicillin susceptibility (MIC≥1
mg/L) are commonly found in group I and II
Strains belonging to group III and group III like are
normally associated with high resistance levels to
ampicillin, as well as cephalosporins
García-Cobos S, Campos J, Lázaro E et al.; Antimicrob Agents Chemother 2007; 51: 2564-73
Resistance genotypes
Genotype 2001-2008 N (%) Genotype 2009-2011 N (%)
gBLNAS 66 (27.5%) gBLNAS 46(18.5%)
Haemophilus influenzae genotypes distribution among the two periods: 2001-2008 
and 2009-2011
gBLPAR 33 (13.7%) gBLPAR 22 (8.9%)
gBLNAR 94 (39.2%) gBLNAR 136 (54.9%)
gBLPACR 47 (19.6%) gBLPACR 44 (17.7%)
Total 240 (100.0%) Total 248 (100.0%)
Barbosa AR, Giufre M, Cerquetti M, Bajanca-Lavado MP (2011); J Antimicrob Chemother 66 (4):788-796
Elsa Guilherme. Master thesis in H. influenzae ampicillin resistance mechanisms  in Portugal: 2009-2012; Universidade de 
Lisboa, 2013
101 BLNAR 
(MIC≥1mg/L)
59 BLNAS
(MIC<1mg/L) 
80 BLPAR
(MIC≥2mg/L)
32 gBLNAS 47 gBLPACR
59%
33 gBLPAR27 gBLNAR*
46%
7 gBLNAS 94 gBLNAR
96%
Resistance genotypes: 2001-2008 
240 strains
141 with mutations in ftsI
44 without mutations in ftsI
141 
strains
124 
(Val547Ile) 
87.9%
136 
(Asn526Lys) 
96.5%
121 
(Asn569Ser) 
85.8%
* Mutations not associated to 
β-lactams resistance mechanism
140 BLNAR 
(MIC≥1mg/L)
42 BLNAS
(MIC<1mg/L) 
66 BLPAR
(MIC≥2mg/L)
18 gBLNAS 44 gBLPACR
67%
22 gBLPAR24 gBLNAR*
57%
4 gBLNAS 136 gBLNAR
97%
Resistance genotypes: 2009-2012 
248 strains
180 with mutations in ftsI
68 without mutations in ftsI
180 
strains
158 
(Val547Ile) 
87.8%
172 
(Asn526Lys) 
95.6%
146
(Asn569Ser) 
81.1%* Mutations not associated to 
β-lactams resistance mechanism
Discussion
Emergence and dissemination of a non-enzymatic resistance
mechanism among Portuguese H. influenzae clinical isolates: a high
percentage of β-lactamase negative strains with reduced
susceptibility or resistance to ampicillin carry mutations in the
ftsI gene (>95%)
High percentage of gBLPACR strains among our BLPAR strains
(>50%)
Revision of the ampicillin breakpoints allow a more efficient
detection and characterization of BLNAR strains, in the
susceptibility routine testing
Ampicillin EUCAST breakpoints are more accurate than CLSI,
since intermediate strains are now considered resistant but still
that most strains with ampicillin MIC ≥1mg/L are not correctly
characterized
Evolution of Ampicillin Resistance
Mechanisms 2001-2008 and 2009-2011
Comparing the first study with the second one we 
observed
Increasing of BLNAR and BLPACR resistance 
genotypes
Increasing of strains characterized in mutational 
group III like
Increasing in genetic diversity
Conclusion
Although a lot of studies have been performed on this
subject more studies are needed to establish adequate
therapeutic and preventive measures to avoid selection
and dissemination of resistant strains
The inappropriate use of oral antibiotics may be
responsible for the selection of this new resistance trait
We would like to emphasize the importance of
continuing surveillance studies as essential tools to
define trends in the antimicrobial resistance of
Haemophilus influenzae
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